Moxetumomab pasudotox in heavily pretreated patients with relapsed/refractory hairy cell leukemia: Results of a pivotal international study.

Robert J. Kreitman,Claire Dearden,Pier Luigi Zinzani,Julio Delgado,Tadeusz Robak,Phillipp D. Le Coutre,Bjørn Tore Gjertsen,Xavier Troussard,G. Saglio,Gail J. Roboz,Lionel Karlin,Douglas E. Gladstone,Kemal Balic,Nathan Standifer,Peng He,Shannon Marshall,Wyndham H. Wilson,Ira Pastan,Nai-Shun Yao,Francis J. Giles

Moxetumomab pasudotox in heavily pretreated patients with relapsed/refractory hairy cell leukemia: Results of a pivotal international study.

2018

7004Background: A pivotal multicenter, single-arm study evaluated moxetumomab pasudotox, a first-in-class recombinant immunotoxin, in patients (pts) with relapsed/refractory hairy cell leukemia (HC...

Keywords:

Pathology
Moxetumomab pasudotox
Oncology
Internal medicine
Refractory hairy cell leukemia
Medicine
in patient
Cancer research
recombinant immunotoxin
relapsed refractory
Hairy cell leukemia

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations